These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 36155987)

  • 1. Investigation of urinary metabolomics in a phase I hookworm vaccine trial in Gabon.
    Betouke Ongwe ME; Mouwenda YD; Stam KA; Kremsner PG; Lell B; Diemert D; Bethony J; Bottazzi ME; Hotez PJ; Leeuwen RV; Grobusch MP; Adegnika AA; Mayboroda OA; Yazdanbakhsh M
    PLoS One; 2022; 17(9):e0275013. PubMed ID: 36155987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and immunogenicity of the Na-APR-1 hookworm vaccine in infection-naïve adults.
    Diemert DJ; Zumer M; Campbell D; Grahek S; Li G; Peng J; Elena Bottazzi M; Hotez P; Bethony J
    Vaccine; 2022 Oct; 40(42):6084-6092. PubMed ID: 36114129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and immunogenicity of the co-administered Na-APR-1 and Na-GST-1 hookworm vaccines in school-aged children in Gabon: a randomised, controlled, observer-blind, phase 1, dose-escalation trial.
    Zinsou JF; Diemert DJ; Dejon-Agobé JC; Adégbité BR; Honkpehedji YJ; Vodonou KG; Bikangui R; Edoa JR; Massinga Loembe M; Li G; Yazdanbakhsh M; Bottazzi ME; van Leeuwen R; Kremsner PG; Hotez PJ; Bethony JM; Grobusch MP; Adegnika AA
    Lancet Infect Dis; 2024 Jul; 24(7):760-774. PubMed ID: 38513684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and immunogenicity of co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in Gabonese adults: a randomised, controlled, double-blind, phase 1 dose-escalation trial.
    Adegnika AA; de Vries SG; Zinsou FJ; Honkepehedji YJ; Dejon Agobé JC; Vodonou KG; Bikangui R; Bouyoukou Hounkpatin A; Bache EB; Massinga Loembe M; van Leeuwen R; Molemans M; Kremsner PG; Yazdanbakhsh M; Hotez PJ; Bottazzi ME; Li G; Bethony JM; Diemert DJ; Grobusch MP;
    Lancet Infect Dis; 2021 Feb; 21(2):275-285. PubMed ID: 32926834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of T cell responses to co-administered hookworm vaccine candidates Na-GST-1 and Na-APR-1 in healthy adults in Gabon.
    Mouwenda YD; Betouke Ongwe ME; Sonnet F; Stam KA; Labuda LA; De Vries S; Grobusch MP; Zinsou FJ; Honkpehedji YJ; Dejon Agobe JC; Diemert DJ; van Leeuwen R; Bottazzi ME; Hotez PJ; Kremsner PG; Bethony JM; Jochems SP; Adegnika AA; Massinga Loembe M; Yazdanbakhsh M
    PLoS Negl Trop Dis; 2021 Oct; 15(10):e0009732. PubMed ID: 34597297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunogenicity of the Na-GST-1 hookworm vaccine in Brazilian and American adults.
    Diemert DJ; Freire J; Valente V; Fraga CG; Talles F; Grahek S; Campbell D; Jariwala A; Periago MV; Enk M; Gazzinelli MF; Bottazzi ME; Hamilton R; Brelsford J; Yakovleva A; Li G; Peng J; Correa-Oliveira R; Hotez P; Bethony J
    PLoS Negl Trop Dis; 2017 May; 11(5):e0005574. PubMed ID: 28464026
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a peptide vaccine against hookworm infection: Immunogenicity, efficacy, and immune correlates of protection.
    Shalash AO; Becker L; Yang J; Giacomin P; Pearson M; Hussein WM; Loukas A; Toth I; Skwarczynski M
    J Allergy Clin Immunol; 2022 Jul; 150(1):157-169.e10. PubMed ID: 35278494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PRIMVAC vaccine adjuvanted with Alhydrogel or GLA-SE to prevent placental malaria: a first-in-human, randomised, double-blind, placebo-controlled study.
    Sirima SB; Richert L; Chêne A; Konate AT; Campion C; Dechavanne S; Semblat JP; Benhamouda N; Bahuaud M; Loulergue P; Ouédraogo A; Nébié I; Kabore M; Kargougou D; Barry A; Ouattara SM; Boilet V; Allais F; Roguet G; Havelange N; Lopez-Perez E; Kuppers A; Konaté E; Roussillon C; Kanté M; Belarbi L; Diarra A; Henry N; Soulama I; Ouédraogo A; Esperou H; Leroy O; Batteux F; Tartour E; Viebig NK; Thiebaut R; Launay O; Gamain B
    Lancet Infect Dis; 2020 May; 20(5):585-597. PubMed ID: 32032566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New tools for NTD vaccines: A case study of quality control assays for product development of the human hookworm vaccine Na-APR-1M74.
    Pearson MS; Jariwala AR; Abbenante G; Plieskatt J; Wilson D; Bottazzi ME; Hotez PJ; Keegan B; Bethony JM; Loukas A
    Hum Vaccin Immunother; 2015; 11(5):1251-7. PubMed ID: 26018444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in neglected tropical disease vaccines: Developing relative potency and functional assays for the Na-GST-1/Alhydrogel hookworm vaccine.
    Brelsford JB; Plieskatt JL; Yakovleva A; Jariwala A; Keegan BP; Peng J; Xia P; Li G; Campbell D; Periago MV; Correa-Oliveira R; Bottazzi ME; Hotez PJ; Diemert D; Bethony JM
    PLoS Negl Trop Dis; 2017 Feb; 11(2):e0005385. PubMed ID: 28192438
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and immunogenicity of the chlamydia vaccine candidate CTH522 adjuvanted with CAF01 liposomes or aluminium hydroxide: a first-in-human, randomised, double-blind, placebo-controlled, phase 1 trial.
    Abraham S; Juel HB; Bang P; Cheeseman HM; Dohn RB; Cole T; Kristiansen MP; Korsholm KS; Lewis D; Olsen AW; McFarlane LR; Day S; Knudsen S; Moen K; Ruhwald M; Kromann I; Andersen P; Shattock RJ; Follmann F
    Lancet Infect Dis; 2019 Oct; 19(10):1091-1100. PubMed ID: 31416692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utility of urinary cytokine levels as predictors of the immunogenicity and reactogenicity of AS01-adjuvanted hepatitis B vaccine in healthy adults.
    Burny W; Hervé C; Caubet M; Yarzabal JP; Didierlaurent AM
    Vaccine; 2022 Apr; 40(19):2714-2722. PubMed ID: 35367070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and immunogenicity of CpG 1018 and aluminium hydroxide-adjuvanted SARS-CoV-2 S-2P protein vaccine MVC-COV1901: interim results of a large-scale, double-blind, randomised, placebo-controlled phase 2 trial in Taiwan.
    Hsieh SM; Liu MC; Chen YH; Lee WS; Hwang SJ; Cheng SH; Ko WC; Hwang KP; Wang NC; Lee YL; Lin YL; Shih SR; Huang CG; Liao CC; Liang JJ; Chang CS; Chen C; Lien CE; Tai IC; Lin TY
    Lancet Respir Med; 2021 Dec; 9(12):1396-1406. PubMed ID: 34655522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study.
    Cohen D; Atsmon J; Artaud C; Meron-Sudai S; Gougeon ML; Bialik A; Goren S; Asato V; Ariel-Cohen O; Reizis A; Dorman A; Hoitink CWG; Westdijk J; Ashkenazi S; Sansonetti P; Mulard LA; Phalipon A
    Lancet Infect Dis; 2021 Apr; 21(4):546-558. PubMed ID: 33186516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Comparison of the Quality of Informed Consent for Clinical Trials of an Experimental Hookworm Vaccine Conducted in Developed and Developing Countries.
    Diemert DJ; Lobato L; Styczynski A; Zumer M; Soares A; Gazzinelli MF
    PLoS Negl Trop Dis; 2017 Jan; 11(1):e0005327. PubMed ID: 28114401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.
    Bennett SR; McCarty JM; Ramanathan R; Mendy J; Richardson JS; Smith J; Alexander J; Ledgerwood JE; de Lame PA; Royalty Tredo S; Warfield KL; Bedell L
    Lancet Infect Dis; 2022 Sep; 22(9):1343-1355. PubMed ID: 35709798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial.
    Agnandji ST; Fernandes JF; Bache EB; Obiang Mba RM; Brosnahan JS; Kabwende L; Pitzinger P; Staarink P; Massinga-Loembe M; Krähling V; Biedenkopf N; Fehling SK; Strecker T; Clark DJ; Staines HM; Hooper JW; Silvera P; Moorthy V; Kieny MP; Adegnika AA; Grobusch MP; Becker S; Ramharter M; Mordmüller B; Lell B; ; Krishna S; Kremsner PG
    PLoS Med; 2017 Oct; 14(10):e1002402. PubMed ID: 28985239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity and safety of three aluminium hydroxide adjuvanted vaccines with reduced doses of inactivated polio vaccine (IPV-Al) compared with standard IPV in young infants in the Dominican Republic: a phase 2, non-inferiority, observer-blinded, randomised, and controlled dose investigation trial.
    Rivera L; Pedersen RS; Peña L; Olsen KJ; Andreasen LV; Kromann I; Nielsen PI; Sørensen C; Dietrich J; Bandyopadhyay AS; Thierry-Carstensen B
    Lancet Infect Dis; 2017 Jul; 17(7):745-753. PubMed ID: 28454674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inflammatory parameters associated with systemic reactogenicity following vaccination with adjuvanted hepatitis B vaccines in humans.
    Burny W; Marchant A; Hervé C; Callegaro A; Caubet M; Fissette L; Gheyle L; Legrand C; Ndour C; Tavares Da Silva F; van der Most R; Willems F; Didierlaurent AM; Yarzabal J;
    Vaccine; 2019 Mar; 37(14):2004-2015. PubMed ID: 30850240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.